Eli Lilly sends strong message on vaccine strategy

Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days.

But what if surviving shingles was only half the battle?

New research suggests the virus behind it could raise your risk of stroke and dementia years after the infection clears.

And that finding is now driving one of the boldest strategic bets Eli Lilly has made in its 150-year history.

On May 28, Eli Lilly's (LLY) chief scientific officer laid out why the pharmaceutical giant is allocating nearly $4 billion to gain a first-mover advantage.

Why common infections are scarier than you think

For decades, the medical world treated infections and chronic disease as separate problems. New research is rewriting that assumption entirely.

Scientists now have strong evidence linking Epstein-Barr virus (EBV), the bug behind mono, to multiple sclerosis.

Related: BofA sees more upside in Eli Lilly stock

They've also found that shingles increases stroke risk, and that getting vaccinated against shingles is associated with a meaningfully lower risk of developing dementia later in life.

"Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer, and infertility," explained Chief Scientific and Product Officer Daniel Skovronsky.

That science is now Lilly's investment thesis.

Lilly's $3.83B vaccine shopping spree, explained

On May 26, Lilly announced deals to acquire three companies: Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc.

Each one targets a different piece of the same bigger picture.

• Curevo is developing a next-generation shingles vaccine. The current standard of care works well, but many patients skip the required second dose because the side effects, including activity-limiting fatigue, chills, and injection-site pain, can be rough.
• In a head-to-head Phase 2 trial, Curevo's candidate matched the immune response of the existing vaccine but cut those side effects by more than half. Lilly is paying up to $1.5 billion for the company.
• LimmaTech Biologics is building vaccines against bacteria that are increasingly resistant to antibiotics. Its lead program targets Staphylococcus aureus, the leading cause of surgical-site infections. The deal is valued at up to $780 million.
• Vaccine Company is developing a vaccine for the Epstein-Barr virus, the same virus that scientists now link to multiple sclerosis and several cancers. Its lead candidate is Phase 1-ready. Lilly is paying up to $1.55 billion for the purchase.

Add it all up, and Lilly just committed close to $3.83 billion to vaccines it expects could prevent infections and the chronic diseases that follow them.

Lilly is not chasing the vaccine giants

At a recent healthcare conference Skovronsky was clear about one thing: Lilly is not trying to become the next Pfizer or Moderna. Skovronsky stated:

"It's not that we have an ambition to compete with the vaccine companies today where they are. But we want to invest where they're not investing for the next generation of important pathogens."

Lilly is placing long bets on science that most of its competitors haven't prioritized yet.

It's the same playbook Lilly ran in obesity. The company worked on incretin biology for decades before tirzepatide, sold as Mounjaro and Zepbound, became the biggest product launch in pharmaceutical history.

More Medicare/Medicaid:

• AARP raises a red flag on Social Security, Medicare
• If your Medicare plan was canceled, do this now
• AARP explains huge new Medicare change coming soon

Skovronsky pointed to a simple rule that guides Lilly's deal-making: find great people working on great science in areas of real unmet need, and invest early.

That approach has kept Lilly ahead of the pack in metabolic disease. The company is now applying the same logic to infectious diseases.

The bigger implication for long-term investors is this. If shingles vaccination can reduce dementia risk at a population level, a more tolerable vaccine that more people complete could have a public health impact that goes well beyond its sticker price.

Lilly just bet nearly $4 billion that the market hasn't priced that in yet.

Related: Early Eli Lilly stock investors now earn a 9% dividend yield-on-cost

The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

This story was originally published May 31, 2026 at 8:47 AM.